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neither depletion of tnF-α, tnF-related apoptosis-induc-
ing ligand, tnF-like weak inducer of apoptosis or Fasl 
alone nor in combination induced an augmentation of 
tumour burden. to show whether an alternative cell death 
pathway is involved, we next generated a/J mice deficient 
for perforin. after challenging with nnK, mice deficient 
for perforin showed an increase in tumour number and vol-
ume compared to wild-type a/J mice. In summary, our data 
suggest that nK cells and perforin-mediated cytolysis are 
critically involved in the protection from lung cancer giving 
promise for further immunotherapeutic strategies for this 
disease.
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Abbreviations
nSClC  non-small cell lung cancer
nnK  nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone
nK  natural killer
tnF  tumor necrosis factor
traIl  tumor necrosis factor-related apoptosis-induc-
ing ligand
tWeaK  tnF-like weak inducer of apoptosis
PKO  Perforin-deficiency
Introduction
lung cancer is the leading cause of cancer death worldwide 
among men and the second leading cancer site in women. 
In fact, 1.6 million of people were diagnosed with lung can-
cer in 2008 accounting for 13 % of total cases. In the same 
Abstract One alternative approach for the treatment of 
lung cancer might be the activation of the immune system 
using vaccination strategies. However, most of clinical vac-
cination trials for lung cancer did not reach their primary 
end points, suggesting that lung cancer is of low immuno-
genicity. to provide additional experimental information 
about this important issue, we investigated which type of 
immune cells contributes to the protection from lung cancer 
development. therefore, a/J mice induced for lung adeno-
mas/adenocarcinomas by the tobacco-specific nitrosamine 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (nnK) 
were depleted of CD4+ or CD8+ t cells, CD11b+ mac-
rophages, gr-1+ neutrophils and asialo gM1+ natural killer 
(nK) cells. Subsequent analysis of tumour growth showed 
an increase in tumour number only in mice depleted of nK 
cells. Further asking by which mechanism nK cells sup-
pressed tumour development, we neutralized several death 
ligands of the tumour necrosis factor (tnF) family known 
to be involved in nK cell-mediated cytotoxicity. However, 
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year, 1.4 million patients died from lung cancer according 
to 18 % of total cancer deaths [1]. Despite improved sur-
gery, radio- and chemotherapy, the 5-year survival remains 
low with approx. 16 % [2], suggesting that alternative treat-
ment options are needed for this disease.
Such an alternative treatment strategy might encom-
pass immunotherapy which has been successfully applied 
for other types of cancer such as prostate cancer [3] or 
melanoma [4]. a prerequisite for the administration of 
immunotherapy to certain types of cancer is their immu-
nogenicity which describes the property of cancer cells 
to induce a detectable reaction of the immune system. 
Whether lung cancer is sufficiently accessible to the 
immune system is an unsolved issue yet; 80 % of lung 
cancer is associated with smoking [1]. early studies dem-
onstrated that carcinogens from tobacco smoke provoke 
an impaired function of the immune system. In this con-
text, a decrease in nK cell function was found in both 
mice and humans [5, 6]. However, an impaired function 
of immune effector cells by tobacco smoke would not 
exclude an immunogenicity of lung tumours. Some pre-
liminary answers to the question whether lung cancer is 
able to induce a sufficient reaction of the immune sys-
tem were provided by vaccination studies. these studies 
made use of tumour antigens such as Mage (melanoma-
associated antigen)-a3 or Mucin 1 which are known to 
be overexpressed in non-small cell lung cancer (nSClC) 
and associated with poor prognosis [7, 8]. Phase II clini-
cal trials were conducted using these proteins for vacci-
nation. albeit trends for a positive clinical response to 
both vaccines were detectable, both studies did not reach 
their primary endpoint in terms of significantly prolonged 
survival [9, 10]. Combining the results of these clinical 
trials together with the demonstrated immunosuppression 
by tobacco smoke, these data indicate that lung cancer is 
not or only a weak inducer of an immune response. How-
ever, this conclusion might be amended by an encourag-
ing clinical trial using the vaccine belagenpumaucel-l 
(lucanixtM) which is a mixture of allogeneic nSClC 
cell lines stably transfected to secret an antisense nucleo-
tide to tgF-β. this trial demonstrated a survival benefit 
of patients with nSClC as well as an immune reaction to 
the vaccine [11].
the aim of the present work was to further shed light 
into the matter how the immune system is involved in 
the protection from lung cancer. to this end, we used a 
mouse model of chemically induced lung cancer. a/J 
mice treated with the tobacco-specific nitrosamine 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (nnK) 
developed adenomas/adenocarcinomas of the lung [12, 
13] and are a well-known mouse model mainly used 
for chemoprevention studies. In this context, it was 
shown that certain substances such as isothiocyanates 
or methoxsalen which are believed to inhibit the muta-
genic activation of nnK were able to decrease tumour 
growth in a/J mice [14, 15]. also, FtI-276 an inhibitor 
of the enzyme farnesyltransferase which facilitates the 
activation of the proto-oncogene ras demonstrated ben-
eficial effects in the a/J mouse model [16]. the effect of 
FtI-276 was attributed to mutations of the K-ras gene 
shown for a high percentage of lung tumours in a/J mice 
[17, 18]. However, only a few data exist about how the 
immune system contributes to the carcinogenesis in a/J 
mice. Splenic and peripheral nK cell number seems to 
be lower in a/J mice compared with C57Bl/6 mice [19], 
and their cytolytic activity was shown to be lower com-
pared to strains of mice which are not susceptible for the 
development of lung cancer [20]. Moreover, administra-
tion of nnK was reported to further decrease the activity 
of splenic nK cells in a/J mice, an effect which was con-
verted by the administration of non-steroidal anti-inflam-
matory drugs [5]. Since non-steroidal anti-inflammatory 
drugs were additionally shown to inhibit tumour growth 
in nnK-induced a/J mice [21], nK cells were attributed 
to play a role in the carcinogenesis of this tumour model. 
Whether other immune cells contribute to the develop-
ment of tumours in a/J mice and which mechanisms 
might be utilized has been investigated in the study pre-
sented here.
Materials and methods
reagents
nnK was purchased from toronto research Chemi-
cals, Canada. the stock solution was prepared by solving 
100 mg nnK in 200 μl DMSO. the stock solution was 
further diluted to a final volume of 10 ml with saline. From 
this solution, 200 μl (2 mg nnK) were injected to mice. 
For depletion of immune cells, the following antibodies 
were used: rat anti-CD4, clone gK 1.5 [22]; rat anti-CD8, 
clone 53-6.7 [23, 24]; rat anti-CD11b, clone 5C6 [25]; and 
rat anti-gr-1, clone rB6-8C5 [26], all produced in the lab-
oratory of Hideo Yagita. rabbit anti-asialo gM1 purchased 
from Wako Pure Chemical Industries, Osaka, Japan, was 
used for the depletion of nK cells [23]. Cytokines of the 
tnF family were depleted by the following antibodies: 
rat anti-traIl, clone n2B2 [27]; rat anti-tWeaK, clone 
MtW-1 [28]; and hamster anti-Fasl, clone MFl4 [29], all 
produced in the laboratory of Hideo Yagita. In addition, rat 
anti-tnF, clone V1q [30] which was prepared in the labo-
ratory of Werner Falk was used for neutralization of tnF-
α. Control groups were treated with rat Igg or rabbit Igg 
(both from Sigma, St. louis, MO) or hamster Igg (Jackson 
Immunoresearch, Suffolk, UK).
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Handling of mice
all animal experiments were approved by the Kanton-
ale tierversuchskommission (Kanton Bern, Switzerland). 
Five-week-old female a/J mice were obtained from Jack-
son laboratories (Bar Harbor, Me) and housed in iso-
lated ventilated cages. treatment was applied as described 
below. all applications of antibodies and nnK were per-
formed as i.p. injections. after completion of the treatment, 
mice were killed by an overdose of pentobarbital, and lungs 
were harvested. the tumour number was counted, and the 
size of tumours was measured using a digital calliper. the 
latter experiments were all executed with two investigators 
in which the person who measured tumour number and vol-
ume was blinded.
generation of perforin-deficient a/J mice
Perforin-deficient (PKO) mice on a C57Bl/6 background 
[31] were kindly provided by Hans Hengartner (Institute 
of experimental Immunology, University of Zurich, Swit-
zerland). these mice were backcrossed for ten generations 
with a/J mice. Mice with mutated perforin allele were 
identified by PCr analysis as described before [32]. In 
brief, genomic Dna was isolated from ear biopsies using 
the Dneasy Blood and tissue kit from QIagen (Valen-
cia, Ca, USa). For the PCr, two different primer pairs 
were used. 5′-ttt ttg aga CCC tgt aga CCC a-3′, 
5′-gCa tCg CCt tCt atC gCC ttC t-3′) which gives 
no product for the wild-type (wt) allele and which produces 
a band of 665 bp for the mutated perforin allele. 5′-CCg 
gtC Ctg aaC tCC tgg CCa a-3′, 5′-CCC Ctg CaC 
aCa tta Ctg gaa g-3′ yields a 300-bp fragment for 
wt and a 1,300-bp fragment for the mutated allele. Only 
the second primer pair was able to distinguish between 
mice harbouring a heterozygous or homozygous muta-
tion of the perforin allele. Perforin-deficient a/J mice mice 
used in this study will be archived and distributed as live 
mice or frozen material via the european Mouse Mutant 
archive (eMMa), which is part of the InFraFrOntIer 
research Infrastructure (www.infrafrontier.eu) under the 
strain name a.B6-Prf1tm1Sdz/Biat (eMMa ID eM:07765).
analysis of Foxp3-positive regulatory t cells (tregs or 
CD4+Foxp3+ cells) and myeloid-derived suppressor 
(CD11+gr-1+) cells
Splenocytes from wt a/J mice and a/J mice deficient for 
perforin were freshly isolated as described before [33]. 
Cells were then incubated with Fc receptor-blocking mab 
(clone 2.4g2, BD Biosciences) followed by incubation 
with fluorochrome-labelled mabs. For tregs, after stain-
ing for CD4, cells were fixed and permeabilized followed 
by incubation with the anti-Foxp3 ab. Staining was meas-
ured on an lSrII flow cytometer (BD Biosciences) and 
analysed using FlowJo software (tree Star, ashland, Or).
the following abs were used: anti-CD4 (clone rM4-5, 
Caltag), anti-Foxp3 (clone 150D, Biolegend), anti-CD11 
(clone M1/70, Biolegend) and anti-gr-1 (clone rB6-8C5, 
Caltag).
Cytotoxicity assay
nK cell-sensitive Yac-1 cells (atCC, Manassas, Va) were 
used as target cells. Yac-1 cells were labelled with 5-(and-
6)-carboxyfluorescein diacetate succinimydyl ester (CFSe) 
using the 7-aaD/CFSe Cell-Mediated Cytotoxicity assay 
Kit from abcam (Cambridge, UK). labelled Yac-1 cells 
were then added to a 96-well plate with 1 × 105 cells per 
well. as effector cells, freshly isolated splenocytes from wt 
a/J mice, aJ.PKO+/− or aJ.PKO−/− mice were added at an 
effector/target ratio of 20:1. the plate was centrifuged for 
4 min at 30×g to allow cell contact followed by incuba-
tion for 4 h at 37 °C. Immediately before analysis, samples 
were incubated with 7-amino-actinomycin D (7-aaD), 
and death of target cells was subsequently determined by 
flow cytometry analysing the number of CFSe+/7-aaD+ 
events. the final experiments were realized in a manner 
that the conducting person was blinded for the groups of 
mice from which splenocytes were isolated.
Statistical analysis
Differences in tumour number and volume were evaluated 
for significance using Student’s t test or Mann–Whitney U 
test. a P < 0.05 was considered statistically significant.
Results
Depletion of nK cells promotes tumour development 
in a/J mice
First, we examined whether certain types of immune cells 
contribute to the development of lung cancer in a/J mice. 
therefore, mice were depleted of CD4+ or CD8+ t cells, 
CD11b+ macrophages, gr-1+ neutrophils or asialo gM1+ 
nK cells using antibodies which were shown before to 
effectively reduce the number of targeted cells [22–26]. 
at 6 weeks of age, depletion was initiated with 100 μg 
of antibody for CD4 [22], CD8 [23, 24], CD11b [25] and 
gr-1 [26] and 300 μg for asialo gM1 [23], each in a vol-
ume of 200 μl. treatment was performed twice a week for 
20 weeks. two days after the first application of deplet-
ing antibodies, a single dose of 2 mg nnK was injected to 
mice. as a result, neither the depletion of CD4-, CD8- or 
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CD11b-positive cells nor depletion of neutrophils yielded 
enhanced tumour growth compared to saline-treated mice 
or to mice which received the respective control Igg 
(Fig. 1a, b). Only the treatment with anti-asialo gM1, an 
antibody which has been widely used for the depletion of 
nK cells, evoked a significant effect on tumour growth. 
While there was no difference between saline-treated mice 
and mice treated with rabbit Igg, nK cell-depleted mice 
showed a significantly increased tumour number com-
pared to either of these control groups (n = 5; P = 0.047 
saline vs anti-asialo gM1 and P = 0.039 rabbit Igg vs anti-
asialo gM1, Fig. 1c). no difference was found between the 
groups when analysing the tumour volume (Fig. 1d). How-
ever, the missing difference in tumour volume might be a 
result of the chosen time point for killing of the animals 
and would have been different most likely to a later time 
point.
Death-inducing cytokines of the tnF family are not 
involved in nK cell-mediated tumour suppression in a/J 
mice
Providing a contribution of nK cells to the suppression 
of lung cancer in a/J mice, we next asked which mecha-
nisms nK cells used to suppress tumour growth in these 
mice. Death-inducing cytokines of the tnF family, espe-
cially tnF-related apoptosis-inducing ligand (traIl) 
and Fasl (CD95l), were demonstrated to be involved in 
nK cell-mediated cytotoxicity [34]. to explore whether 
and which of these cytokines might be responsible for the 
ba
dc
Fig. 1  effect of immune cell depletion on lung tumour development 
in a/J mice induced with nnK. Depletion of CD4+ or CD8+ t cells, 
macrophages, neutrophiles and nK cells was initiated in 6-week-old 
a/J mice using i.p. injections with 100 μg of anti-CD4, anti-CD8, 
anti-CD11b or anti-gr-1 mab or 300 μg of anti-asialo gM1 ab, 
respectively. two days after first application of depleting antibod-
ies, mice were induced for lung cancer with 2 mg of nnK. treat-
ment with antibodies or control Igg was performed twice a week for 
20 weeks. the tumour burden was assessed in a blinded manner. a 
tumour number and b tumour volume for mice depleted of CD4+ or 
CD8+ t cells, macrophages or neutrophils demonstrated no signifi-
cant differences compared to saline- or control rat Igg-treated mice. c 
Depletion of nK cells with anti-asialo gM1 ab showed an increased 
tumour number compared to saline-treated mice or mice treated with 
control rabbit Igg (n = 5; P = 0.047 saline vs anti-asialo gM1 and 
P = 0.039 rabbit Igg vs anti-asialo gM1, Student’s t test). d Differ-
ences in tumour volume of nK cell-depleted mice were not signifi-
cant compared to control groups. *P < 0.05
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effects of nK cell-mediated tumour suppression, a/J mice 
were depleted of traIl, Fasl, tnF-α or tWeaK using 
specific neutralizing antibodies [27–30]. at 6 weeks of 
age, mice received a single dose of 2 mg nnK followed 
by application of 100 μg of neutralizing antibody. Con-
trol groups were treated with saline, or rat or hamster Igg. 
treatment with antibodies was carried out twice weekly 
for 21 weeks. the subsequent analysis of tumour burden 
in the lung revealed no differences between groups neu-
tralized for these cytokines and control groups (Fig. 2a–
d). to exclude that this result was caused by redundancy 
of the neutralized cytokines, we next performed an exper-
iment where traIl, Fasl and tWeaK were neutralized 
in combination. the control group received the respective 
amount of hamster and rat Igg. Similarly to the separate 
neutralization, the combined neutralization of traIl, 
Fasl and tWeaK had no effect on tumour growth, 
neither on tumour number nor on tumour volume (Fig. 2e, 
f). Collectively, these data suggest that cytokines of the 
tnF family do not considerably contribute to the suppres-
sion of lung cancer in a/J mice.
tumour suppression in a/J mice depends 
on perforin-mediated cytotoxicity
another mechanism for cell death induced by nK cells is 
represented by the perforin/granzyme pathway. While the 
function of certain members of the granzyme family for 
immunosurveillance of cancer is uncertain yet, it has been 
shown that nK cell activity against a number of tumours 
highly depends on an intact perforin molecule [35]. to 
answer the question whether perforin-mediated cytolysis 
is involved in nK cell-mediated tumour suppression in a/J 
mice, a/J mice deficient for perforin (referred as aJ.PKO) 
b
dc
a
fe
Fig. 2  neutralization of death-inducing tnF family ligands has no 
influence on tumour development in nnK-treated a/J mice. Six-
week-old female a/J mice were exposed to a single dose of 2 mg 
nnK and subsequently treated with antibodies neutralizing tnF-α, 
traIl, tWeaK or Fasl. treatment with antibodies or control Igg 
was performed twice a week for 21 weeks. tumour number (a) and 
(c) and tumour volume (b) and (d) of animals depleted of single tnF 
family ligands revealed no differences in tumour growth compared to 
saline- or Igg-treated groups. tumour number (e) and tumour volume 
(f) of mice depleted of traIl, Fasl and tWeaK in combination 
were statistically not different from those of the control Igg-treated 
group
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were generated. these mice were induced for lung can-
cer with 2 mg nnK at 6 weeks of age. twenty-two weeks 
later, mice were killed and the tumour burden of a/J mice 
heterozygously (+/−) or homozygously (−/−) deficient for 
perforin were compared with wild-type (wt) a/J mice. We 
performed eight independent experiments with varying 
numbers of animals. From these eight experiments, one 
was excluded due to an exceptional high tumour number 
and volume in all three experimental groups. analysis of 
the remaining animals revealed that a/J mice deficient for 
perforin had a higher susceptibility for nnK-induced lung 
cancer. Both aJ.PKO+/− and aJ.PKO−/− showed a signifi-
cantly higher number of lung tumours compared with wt 
a/J mice (n = 17 for wt, n = 42 for aJ.PKO+/−, n = 26 for 
aJ.PKO−/−; P = 0.031 for wt vs aJ.PKO+/−, P = 0.036 for 
wt vs aJ.PKO−/−; Fig. 3a). the assessment of tumour vol-
ume demonstrated a significant difference for aJ.PKO+/− 
compared to wt (P = 0.034; Fig. 3b) but not for aJ.PKO−/− 
compared to wt (P = 0.16; Fig. 3b).
to rule out that immunosuppression other than decreased 
nK cell activity might play a role in aJ.PKO mice, we 
measured the level of tregs (CD4+Foxp3+ cells) and the 
level of myeloid-derived suppressor (CD11+gr-1+) cells. 
analysis of these cell types in the splenocyte population 
revealed no difference between wt a/J mice and aJ.PKO 
mice (Fig. 4a, b), indicating that decreased immunosur-
veillance in perforin-deficient mice is due to an impaired 
function of nK cells. to provide more direct evidence for 
this suggestion, we subsequently measured in vitro cyto-
toxic splenic nK cell activity of perforin-deficient mice. as 
shown in Fig. 5, the cytotoxic activity of both aJ.PKO−/+- 
and aJ.PKO−/−-derived splenic nK cells was significantly 
lower than the nK cell activity of wt a/J mice. these 
a
b
Fig. 3  Influence of perforin deficiency on lung tumour development. 
Six-week-old female aJ.PKO mice (heterozygous or homozygous) 
were exposed to 2 mg nnK. twenty-two weeks later, lung tissue was 
analysed. a aJ.PKO+/− and aJ.PKO−/− had a significantly higher 
number of lung tumours compared with wt a/J mice (n = 17 for wt, 
n = 42 for aJ.PKO+/−, n = 26 for aJ.PKO−/−; P = 0.031 for wt vs 
aJ.PKO+/−, P = 0.036 for wt vs aJ.PKO−/−). b the tumour volume 
was significantly higher in aJ.PKO+/− compared to wt (P = 0.034) 
but not in aJ.PKO−/− compared to wt (P = 0.16); Mann–Whitney U 
test. *P < 0.05
a
b
Fig. 4  analysis of tregs (CD4+Foxp3+ cells) and myeloid-derived 
suppressor (CD11+gr-1+) cells in perforin-deficient a/J mice. Sple-
nocytes from wt a/J mice, aJ.PKO−/+ and aJ.PKO−/− mice were 
stained with fluorochrome-labelled mabs and analysed by flow 
cytometry
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findings propose that nK cells and the perforin-mediated 
cytolytic pathway indeed contribute to the prevention of 
chemically induced lung cancer.
Discussion
the immunogenicity of lung cancer remains an unsolved 
question until now. as referred above, most of the clinical 
trials for lung cancer using vaccination strategies failed to 
achieve their primary end points. this problem might have 
two reasons: One could be that the antigens used for vacci-
nation were not ideal and the other could be that lung can-
cer is in general not able to induce a sufficient reaction of 
the immune system. Our study was delineated to elucidate 
the second issue whether lung cancer has the ability to pro-
voke an immune reaction or not.
In a first set of experiments, a/J mice which were 
induced for lung cancer with nnK were depleted of differ-
ent types of immune cells. However, depletion of CD4+ t 
cells, CD8+ t cells, CD11b+ macrophages or gr-1+ neu-
trophils did not significantly affect the tumour burden in 
a/J mice. these results were not expected because the defi-
ciency of Foxp3-positive regulatory t cells was shown to 
reduce tumour growth in a/J mice [36]. tregs are a subset of 
CD4-positive t cells. Since we depleted in our experiments 
all CD4-positive cells, one might ask whether a proposed 
beneficial effect of losing these tregs had been negotiated 
by the loss of effector CD4+ t cells. therefore, we do not 
exclude from our data that in wild-type a/J mice CD4-pos-
itive cells other than tregs contribute to the suppression of 
lung cancer.
Our results further demonstrated that depletion of nK 
cells resulted in an increased tumour number, suggesting 
a pivotal role of nK cells for the control of tumour growth 
in this lung cancer model. nK cells execute their cyto-
toxic effects either by direct target cell lysis or by secre-
tion of cytokines such as interferon-γ, but without the 
b
aFig. 5  Cytolytic nK cell activity in perforin-deficient a/J mice. nK 
cell-sensitive Yac-1 cells were used as target cells. Yac-1 cells were 
labelled with 5-(and-6)-carboxyfluorescein diacetate succinimydyl 
ester (CFSe). as effector cells, freshly isolated splenocytes from wt 
a/J mice, aJ.PKO+/− or aJ.PKO−/− were added at an effector/tar-
get ratio of 20:1 followed by an incubation for 4 h at 37 °C. Sam-
ples were then stained with 7-amino-actinomycin D (7-aaD), and 
death of target cells was subsequently determined by flow cytometry 
analysing the number of CFSe+7/aaD+ events. a representative 
dot plots for target and effector cells alone (upper panel) and when 
incubated together (lower panel). b Comparison of cytotoxic nK 
cell activity of the different groups of mice with n = 3 per group. 
P = 0.0046 wt a/J versus aJ.PKO+/− and P = 0.0031 wt a/J versus 
aJ.PKO−/−, Student’s t test. **P < 0.01
▸
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need of antigen-specific recognition as required for cyto-
toxic t lymphocytes. In this context, nK cell activity was 
shown to be important for the development or rejection 
of MHC class-I-deficient lymphomas [37], and depletion 
of nK cells was also found to promote tumour growth of 
fibrosarcomas [38]. Furthermore, there is evidence that 
lung cancer development depends on the function of nK 
cells. In a recent publication, Kreisel and colleagues dem-
onstrated that depletion of nK cells promoted urethane-
induced lung tumour growth in a mouse strain which is 
normally not susceptible to lung cancer [20]. Moreover, 
nK cells were shown to have lower activity in a/J mice 
[19], which are prone to develop lung cancer induced by 
certain chemicals such as the nitrosamine nnK. nnK 
itself was demonstrated to further reduce nK cell activ-
ity in a/J mice [5], an effect which has been observed 
in human smokers as well [6]. Despite the assumption 
of lower nK cell activity in nnK-induced a/J mice, our 
data suggest that the remaining nK cell activity was suf-
ficient to reduce lung tumour formation. However, once 
the lung tumours are established, another situation might 
arise comprising a direct inhibition of nK cell activity 
by lung cancer cells. thus, it has been shown that lung 
tumour cells from malignant pleural effusions inhibit nK 
cell activity [39], and it was further demonstrated that nK 
cells isolated from lung tumours exhibit decreased cyto-
toxic activity [40].
the mechanisms how nK cells induce direct target cell 
lysis might vary; both the engagement of cytokines of the 
tnF family as well as the perforin-mediated granule exo-
cytosis pathways are known [34]. Many studies were pub-
lished showing a significant contribution of tnF family 
cytokines to the protection from different types of cancer. 
While the presence of traIl and Fasl was demonstrated 
to have anti-cancer attributes [41–43], the genetic abla-
tion or antibody-mediated depletion of tnF-α inhibited 
the development of skin cancer [44, 45]. Similar to tnF-α, 
tWeaK seems to act in a pro-cancerogenic manner [46]. 
However, in our experimental setup, neither the neutraliza-
tion of traIl, Fasl, tWeaK or tnF-α alone nor in com-
bination had an influence on nnK-induced lung tumour 
development. this was somewhat surprising especially 
for traIl since our previous laboratory works provided 
promising results when treating lung cancer cells with this 
cytokine [47, 48]. as an alternative pathway, we found in 
vivo and in vitro evidence that the perforin-mediated path-
way contributes to nK cell-mediated tumour suppression in 
a/J mice, as perforin-deficient a/J mice exhibited increased 
tumour development and reduced cytolytic nK cell activity. 
Moreover, the number of other immunosuppressive cells 
such as tregs was not different in perforin-deficient mice 
compared to their wild-type counterpart what might speak 
against a significant contribution. However, the effect of 
PKO on tumour growth was less pronounced than the effect 
of nK cell depletion. therefore, the involvement of other 
factors such as IFn-γ or lymphotoxin-α which were shown 
before to be involved in nK cell-mediated cytotoxicity can-
not be excluded [49, 50].
Collectively, our data suggest a significant contri-
bution of nK cells to the suppression of lung cancer. 
this finding might have important consequences since 
nK cell activity can be stimulated using the glycolipid 
α-galactosylceramide (α-galCer), which activates invari-
ant nKt cells and dendritic cells to produce IFn-γ and 
Il-12, respectively. Subsequent activation of nK cells by 
IFn-γ and Il-12 is again accompanied by profound pro-
duction of IFn-γ [51]. the effects of α-galCer on nKt 
and nK cells were further explored in clinical trials. While 
systemic administration of α-galCer induced a prolonged 
depletion of nKt cells from peripheral blood [52], the ex 
vivo activation of respective nK cells using α-galCer is 
another promising approach. a phase I/II study includ-
ing patients with advanced or recurrent nSClC has been 
published recently with encouraging results. a prolonged 
survival was observed in patients who showed increased 
IFn-γ production in peripheral blood mononuclear cells 
stimulated with α-galCer [53]. However, further studies 
are needed especially in an adjuvant setting of radically 
resected t1 and t2 nSClC in order to see whether stim-
ulation of nK cells lowers the risk of local or metastatic 
recurrence.
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